| Today's Top Story |  |  | | - Creating therapies with macrocycles could spur biologics development
Comparatively few biologic drugs are making it to the market, and many of those are for rare diseases, writes Nick Terrett, chief science officer at Ensemble Therapeutics. Part of the reason is the difficulty of developing biologic drugs, but the industry could use a paradigm shift in how it develops drugs, Terrett writes. Combining small molecules and biologics could create a new therapy option, the macrocycle, he writes. Xconomy/Boston (2/14)       | Health Care & Policy | | | | - Janssen-Pharmacyclics lymphoma drug gets breakthrough status
The FDA granted breakthrough therapy status to Janssen Biotech and Pharmacyclics' ibrutinib, a Bruton's tyrosine kinase inhibitor, as a treatment for relapsed or refractory mantle cell lymphoma and Waldenström's macroglobulinemia. The companies plan to submit the drug for approval for mantle cell lymphoma in 2013. PharmaTimes (U.K.) (2/14) - Team in Japan clears hurdle on way to trial of iPS cells
An ethics panel at the Institute for Biomedical Research and Innovation in Japan has given the green light for a clinical trial of induced pluripotent stem cells in the treatment of age-related macular degeneration. If Japan's Health Ministry approves the six-patient trial, it could begin this fiscal year. The Japan Daily Press (2/14) | Company & Financial News | | | | - Mexico's international grain research center wins $25M grant
The Carlos Slim Foundation awarded the International Corn and Wheat Improvement Center in Mexico a $25 million grant for new facilities, including a greenhouse and laboratory installations. The research center, also backed by the Bill and Melinda Gates Foundation, develops corn and wheat that can tolerate drought, cold and pests. The center also is researching biotech corn. Fox Business/Dow Jones Newswires (2/13)  | Two courses in four days at MIT Sloan Exec Ed
Learn from world-renowned faculty at MIT Executive Education and make the most of your visit with back-to-back two-day courses. Understand big data, revitalize your digital business model, solve complex business problems, drive strategic innovation.
View 25+ short courses. |
 | Industrial & Environmental | | | | - Canadian cellulosic ethanol producer lands deal to sell lignin
Canada-based Lignol Innovations has signed a deal to supply a European thermoplastics maker with purified lignin, a byproduct of cellulosic ethanol production. "When producing next-generation biofuels from renewable, nonfood feedstocks like wood chips, roughly 25% of the output is lignin," said Ross MacLachlan, president and CEO of Lignol Energy. The lignin can be sold for its calorific value or as a replacement for petroleum-based products, he said. EthanolProducer.com (2/13) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | If you want to live a happy life, tie it to a goal. Not to people or things."
--Albert Einstein,
German-born theoretical physicist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, February 14, 2013
- Wednesday, February 13, 2013
- Tuesday, February 12, 2013
- Monday, February 11, 2013
- Friday, February 08, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment